Related Experiment Video
Updated: Jul 3, 2025
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.8K
Novel Treatment Paradigms: Primary IgA Nephropathy
Haresh Selvaskandan1,2, Jonathan Barratt1,2, Chee Kay Cheung1,2
1Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Kidney International Reports
|February 12, 2024
Summary
IgA nephropathy (IgAN) treatments are evolving, with new therapies targeting its causes. Recent approvals offer hope for patients facing kidney failure, marking progress in managing this common kidney disease.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis globally.
- A significant percentage of IgAN patients develop kidney failure (KF) within 20-25 years, with limited effective treatments historically.
- The lack of effective therapies for IgAN has created a critical unmet need.
Purpose of the Study:
- To review the current, recently approved, and emerging therapeutic strategies for IgA nephropathy.
- To highlight advancements in understanding IgAN pathophysiology driving new treatment development.
- To discuss the impact of surrogate endpoints like proteinuria reduction on accelerated drug approval.
Main Methods:
- Review of current literature on IgA nephropathy pathophysiology and therapeutics.
- Analysis of recently approved medications for IgAN.
- Discussion of emerging therapeutic targets and agents in clinical development.
Main Results:
- Two drugs, targeted release formulation (TRF)-budesonide (nefecon) and sparsentan, have received accelerated approval based on proteinuria reduction.
- New therapies are emerging that target key pathophysiological pathways, including mucosal immunity, B-cells, complement, and the endothelin system.
- The therapeutic landscape for IgAN is rapidly changing with novel treatment options.
Conclusions:
- Recent therapeutic advancements and approvals represent significant progress in managing IgA nephropathy.
- Understanding IgAN's complex pathophysiology is crucial for developing targeted and effective treatments.
- The evolving treatment landscape offers improved prospects for patients with IgAN, potentially altering the course towards kidney failure.
More Related Videos
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
449
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
449
01:25Antihypertensive Drugs: Direct Renin Inhibitors
629
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
629
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
164
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
164